LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The program will provide early access to the investigational drug BIBW 2992 to treat patients
with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.
The Compassionate Use Programme will also provide additional safety and efficacy information
on BIBW 2992 use.
Named Patient Use (NPU)